TONIX PHARMACEUTICALS HOLDING CORP. Contract Liability (Deferred Revenue)
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Contract Liability (Deferred Revenue) of $3.82 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-10
- 2026-06-30: Contract with Customer, Liability, Current $3.82M.
- 2026-03-31: Contract with Customer, Liability, Current $4.23M.
- 2025-12-31: Contract with Customer, Liability, Current $3.42M.
- 2025-09-30: Contract with Customer, Liability, Current $2.67M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $3.82M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $4.23M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $3.42M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $2.67M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.01M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.93M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.82M 10-K · filed 2026-03-12 |
| 2023-12-31 | $2.98M 10-K · filed 2025-03-18 |
| 2022-12-31 | $3.27M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |